INCREASED DOPAMINE CONCENTRATION IN LIMBIC AREAS OF BRAIN FROM PATIENTS DYING WITH SCHIZOPHRENIA
INCREASED DOPAMINE CONCENTRATION IN LIMBIC AREAS OF BRAIN FROM PATIENTS DYING WITH SCHIZOPHRENIA
复制标题
DOI：
10.1093/brain/102.2.347
复制
发表时间：
1979-01-01
期刊：
影响因子：
14.5
通讯作者：
IVERSEN, LL
中科院分区：
文献类型：
--
作者：
BIRD, ED;SPOKES, EGS;IVERSEN, LL
多巴胺，去甲肾上腺素，谷氨酸脱羧酶（GAD）和胆碱乙酰转移酶（CAT）进行了测量，在死后的大脑样本从50多名患者死亡与医院诊断的精神分裂症和相同数量的控制。GAD在14个不同的大脑区域进行了测量，并且在控制组和长期患病后死亡的精神分裂症患者中均显着降低。如果对突然死亡的患者的GAD值进行比较，则在对照组和精神分裂症组之间没有观察到显著差异。两组中13个不同脑区的CAT值也没有差异。去甲肾上腺素的值在两组中没有不同的边缘系统的大部分地区或在尾状核，但升高的精神分裂症组在脑桥核和前穿孔物质。然而，这些差异在统计学上并不显著。另一方面，与对照组相比，精神分裂症组的中脑核和前穿孔物质中的多巴胺浓度显著升高（分别为34%和95%），尽管尾状核、壳核、隔核或杏仁核中的多巴胺值没有差异。多巴胺浓度升高的发现，在某些地区的边缘前脑精神分裂症的讨论有关目前的假设参与多巴胺在这种疾病，并确定所观察到的变化是否与抗精神分裂症药物的慢性治疗的困难。
Dopamine, noradrenaline, glutamate decarboxylase (GAD) and choline acetyl-transferase (CAT) were measured in post-mortem brain samples from more than 50 patients dying with a hospital diagnosis of schizophrenia and an equal number of controls. GAD was measured in 14 different brain regions, and was significantly lower in both control and schizophrenia patients who died following a protracted illness. If GAD values from patients who died suddenly were compared, no significant differences were observed between the control and schizophrenia groups. There was also no differences between the CAT values measured in 13 different brain regions in the two groups. Noradrenaline values were not different in the two groups in most limbic areas or in the caudate nucleus, but were elevated in the schizophrenic group in nucleus accumbens and in anterior perforated substance. These differences were not, however, statistically significant. On the other hand dopamine concentrations in nucleus accumbens and in anterior perforated substance were significantly elevated (by 34 and 95 per cent, respectively) in the schizophrenia group as compared with controls, although dopamine values were not different in caudate nucleus, putamen, septal nuclei or amygdala. The finding of elevated concentrations of dopamine in certain areas of the limbic forebrain in schizophrenia is discussed in relation to current hypotheses of the involvement of dopamine in this illness, and the difficulties of determining whether the observed changes are related to chronic treatment with antischizophrenic drugs.